The essence of omnichannel marketing is to ensure that your messaging is reaching your target audience where they spend most ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

In a significant stride toward fostering diversity and inclusivity in dermatology, Medscape Education and the Comprehensive ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...

Syneos Health Communications and Precision AQ led the agency list, while Novartis, Roche and Takeda shared the top client ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...

Avalere Health has announced the appointment of Corrina Safeio as its new president, global marketing and executive vice president, corporate communications. In this role, Safeio will oversee the ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

Sanofi’s investigational BTK inhibitor tolebrutinib has demonstrated promising results in a phase 3 study of patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), which the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has demonstrated significant improvements in itch and hives for patients with chronic spontaneous urticaria (CSU), according to late-stage results shared by ...